Radioembolization
8
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Scout Dose of Resin Microspheres
A Prospective Observational Study on Efficacy of TARE for Early Stage HCC
Ablative Radioembolization of Renal Cell Carcinoma Trial
Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma